ArticlePediatric nephrology (Berlin, Germany)2026
Influence of intrapatient variability in tacrolimus trough levels on acute rejection in pediatric kidney transplant recipients.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTacrolimus is a cornerstone of lifelong immunosuppressive therapy to prevent acute rejection post-kidney transplantation. Tacrolimus intra-patient variability (IPV) is characterized by several pharmacokinetic metrics, including the standard deviation (SD) of tacrolimus troughs, coefficient of variation (CV%), dose-normalized concentration (DNC), and time in therapeutic range (TTR). This study aimed to investigate the influence of TTR, alongside other IPV metrics, on the incidence of acute rejection in the first year after kidney transplantation.
methodsThis single-center retrospective study evaluated the relationship between IPV measures including coefficient of variation (CV%), standard deviation (SD), dose-normalized concentration (DNC), time in therapeutic range (TTR), and acute rejection during the first post-transplant year in 100 pediatric kidney recipients.
resultsPatients were stratified by TTR into two subgroups: TTR < 78% (n = 80) and TTR ≥ 78% (n = 20). The mean CV% of tacrolimus concentration was 37.1 ± 16.6%, with significantly higher variability observed in those with rejection (p = 0.031). Longitudinal analysis showed that differences in trough levels between TTR groups became evident after 3 months (p < 0.001). Multivariable modeling demonstrated that rejection risk was independently associated with higher age (p = 0.002) and post-transplant period beyond 3 months (p = 0.004), rather than TTR itself.
conclusionsIn pediatric kidney transplant patients, the rejection risk was significantly associated with the magnitude of CV% rather than TTR. Special attention is warranted for therapeutic drug monitoring, especially beyond 3 months post-transplant, due to the increased risk of rejection compared to earlier stages post-transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.